Samsca and Solu-cortef drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Samsca (tolvaptan) and Solu-cortef (hydrocortisone sodium succinate). Common drug interactions include haemolytic anaemia among females and cardiac failure among males.

The phase IV clinical study analyzes what interactions people have when they take Samsca and Solu-cortef. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Samsca?

Samsca has active ingredients of tolvaptan. eHealthMe is studying from 8,139 Samsca users. Check the latest studies of Samsca.

What is Solu-cortef?

Solu-cortef has active ingredients of hydrocortisone sodium succinate. eHealthMe is studying from 7,983 Solu-cortef users. Check the latest studies of Solu-cortef.



On Jul, 16, 2026

19 people who take Samsca and Solu-cortef together, and have interactions are studied.

Samsca and Solu-cortef drug interactions.

What are the common drug interactions of Samsca and Solu-Cortef, by gender? *:

female:

  1. Haemolytic anaemia (anaemia due to haemolysis)
  2. Large intestine perforation (hole in large intestine)
  3. Platelet count decreased
  4. Abdominal pain
  5. Arthralgia (joint pain)
  6. Cardiac failure
  7. Collagen disorder (infection and weakness of collagen)
  8. Colon cancer
  9. Drug eruption (adverse drug reaction of the skin)
  10. Epistaxis (bleed from the nose)

male:

  1. Cardiac failure
  2. Hypotension (abnormally low blood pressure)
  3. Bacterial infection
  4. Blood pressure decreased
  5. Chest pain
  6. Cough
  7. Cystitis haemorrhagic (blood in the urine and painful voiding)
  8. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  9. Diarrhoea
  10. Disseminated intravascular coagulation (systemic activation of blood coagulation)

What are the common drug interactions of Samsca and Solu-Cortef, by age (0-1 to 60+)? *:

0-1:

  1. Cardiac failure
  2. Hypotension (abnormally low blood pressure)
  3. Pulmonary hypertension (increase in blood pressure in the lung artery)

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Asthma
  2. Bacterial infection
  3. Chest pain
  4. Cough
  5. Cystitis haemorrhagic (blood in the urine and painful voiding)
  6. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  7. Diarrhoea
  8. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  9. Graft versus host disease in lung (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the lung)
  10. Hypertension (high blood pressure)

40-49:

  1. Abdominal pain
  2. Arthralgia (joint pain)
  3. Cardiac failure
  4. Hepatic enzyme increased
  5. Platelet count decreased
  6. Pulmonary hypertension (increase in blood pressure in the lung artery)

50-59:

  1. Bacteraemia (presence of bacteria in the blood)
  2. Cholangitis (infection of the bile duct)
  3. Transplant rejection (a transplant material is not worked)
  4. Klebsiella infection

60+:

  1. Haemolytic anaemia (anaemia due to haemolysis)
  2. Large intestine perforation (hole in large intestine)
  3. Epistaxis (bleed from the nose)
  4. Haemorrhage (bleeding)
  5. Influenza
  6. Infusion site erosion
  7. Infusion site erythema (reddening of the skin at infusion site)
  8. Infusion site induration
  9. Infusion site pain
  10. Infusion site swelling

What are the existing conditions these people have? *

  1. Diabetes: 5 people, 26.32%
  2. Insomnia (sleeplessness): 4 people, 21.05%
  3. Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 4 people, 21.05%
  4. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 15.79%
  5. Hypotension (abnormally low blood pressure): 3 people, 15.79%
  6. Nephrogenic Anaemia (anaemia due to kidney disease): 3 people, 15.79%
  7. Cardiac Failure Congestive: 3 people, 15.79%
  8. Anuria (failure of the kidneys to produce urine): 3 people, 15.79%
  9. Oedema Due To Cardiac Disease (fluid collection in tissue due to heart disease): 3 people, 15.79%
  10. Pleural Effusion (water on the lungs): 3 people, 15.79%

* Approximation only. Some reports may have incomplete information.

Do you take Samsca and Solu-cortef?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Samsca and Solu-cortef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Solu-cortef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Samsca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Solu-cortef and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tolvaptan and hydrocortisone sodium succinate (the active ingredients of Samsca and Solu-cortef, respectively), and Samsca and Solu-cortef (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: